NoNO Revenue and Competitors
Estimated Revenue & Valuation
- NoNO's estimated annual revenue is currently $18.1M per year.
- NoNO's estimated revenue per employee is $155,000
Employee Data
- NoNO has 117 Employees.
- NoNO grew their employee count by 30% last year.
NoNO's People
Name | Title | Email/Phone |
---|---|---|
1 | President and CEO | Reveal Email/Phone |
2 | Chief Business Officer | Reveal Email/Phone |
3 | Chief Compliance and Strategy Officer | Reveal Email/Phone |
4 | VP Clinical Operations and Safety | Reveal Email/Phone |
5 | Associate Director, QA GCP/PV | Reveal Email/Phone |
6 | Associate Director, Analytical | Reveal Email/Phone |
7 | Senior Director Project Management | Reveal Email/Phone |
8 | Associate Director, Manufacturing | Reveal Email/Phone |
9 | Director, R&D Quality Assurance Strategic Advice | Reveal Email/Phone |
10 | Regulatory Affairs Manager | Reveal Email/Phone |
NoNO Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $4.2M | 27 | 29% | $5M | N/A |
#2 | $1.7M | 11 | 22% | N/A | N/A |
#3 | $0.9M | 11 | -72% | $39.4M | N/A |
#4 | $1M | 13 | -84% | $23.8M | N/A |
#5 | $94.4M | 609 | 8% | N/A | N/A |
#6 | $3.4M | 22 | 10% | N/A | N/A |
#7 | $9.5M | 61 | -68% | N/A | N/A |
#8 | $18.1M | 117 | 30% | N/A | N/A |
#9 | $21.7M | 140 | -6% | N/A | N/A |
#10 | $1M | 13 | -41% | N/A | N/A |
What Is NoNO?
NoNO Inc. is a clinical-stage biotherapeutics company dedicated to the research and development of pharmaceuticals for the treatment of common health disorders with unmet needs, including acute ischemic stroke.
keywords:N/AN/A
Total Funding
117
Number of Employees
$18.1M
Revenue (est)
30%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $29.3M | 117 | 10% | N/A |
#2 | $31.6M | 117 | 1% | N/A |
#3 | $29.3M | 117 | 14% | N/A |
#4 | $29.3M | 117 | N/A | N/A |
#5 | $17.6M | 117 | 9% | N/A |